COEP Insider Trading Activity and SEC Form 4 Filings
COEP insider trading summary
No open-market insider purchases or sales of Coeptis Therapeutics Holdings, Inc. (COEP) have been reported on SEC Form 4 in the past 12 months.
Latest COEP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 12, 2024 | Tara DeSilva | Director | Buy | $261 (466 @ $0.56) |
| Jan 12, 2024 | Tara DeSilva | Director | Buy | $1K (1,800 @ $0.58) |
| Jan 10, 2024 | Brian Cogley | Chief Financial Officer | Buy | $3K (5,000 @ $0.67) |
| Jan 8, 2024 | David Mehalick | CEO and President | Buy | $9K (14,004 @ $0.66) |
| Jan 8, 2024 | David Mehalick | CEO and President | Buy | $4K (6,000 @ $0.67) |
| Jan 5, 2024 | Gene Salkind | Director | Buy | $8K (11,600 @ $0.69) |
| Jan 5, 2024 | Christopher P. Cochran | Director | Buy | $5K (7,000 @ $0.77) |
| Jan 5, 2024 | David Mehalick | CEO and President | Buy | $3K (5,050 @ $0.69) |
| Jan 5, 2024 | Daniel Alexander Yerace | VP of Operations | Buy | $7K (10,850 @ $0.69) |
| Aug 29, 2023 | Gene Salkind | Director | Buy | $4K (4,006 @ $1.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.